Visentin, Andrea
Bonaldi, Laura
Rigolin, Gian Matteo
Mauro, Francesca Romana
Martines, Annalisa
Frezzato, Federica
Imbergamo, Silvia
Scomazzon, Edoardo
Pravato, Stefano
Bardi, Maria Antonella
Cavallari, Maurizio
Volta, Eleonora
Cavazzini, Francesco
Nanni, Maurizio
Del Giudice, Ilaria
Facco, Monica
Guarini, Anna
Semenzato, Gianpietro
Foà, Robin
Cuneo, Antonio
Trentin, Livio
Article History
Received: 27 March 2019
Revised: 15 May 2019
Accepted: 22 May 2019
First Online: 18 June 2019
Competing interests
: A.V. received honoraria from Janssen and Abbvie. L.T. received research funding by Gilead and Janssen, advisory board for Roche, Shire and Abbvie. G.M.R. received research funding by Gilead. F.R.M. advisory board for Janssen, Shire and Abbvie. A.C. advisory board and speaker bureau for Roche, Abbvie, Gilead and Janssen. G.S. board member of Abbvie, Roche, Janssen and Celgene. R.F. advisory board or speaker bureau for Roche, Abbvie, Celgene, Incyte, Amgen, Janssen, Celtrion, Gilead and Novartis. The remaining authors declare no competing interests.
: This study was approved by the local research ethics committee of Padua hospital and informed consent was obtained from all patients.
: This work was supported by funds from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) projects to L.T. (IG-15397), Gilead fellowship program 2017 and 2018 to L.T., Special Program ‘Metastatic disease: the key unmet need in oncology’, AIRC 5 × 1000 (No. 21198) to R.F., Fondo di Ateneo per la Ricerca 2016, 2017 of the University of Ferrara to GMR and F.C., Fondo di Incentivazione alla Ricerca 2017 of the University of Ferrara to G.M.R., Ministero dell’Istruzione, dell’Università e della Ricerca PRIN 2015 to A.C. (2015ZMRFEA). A.V. received a research fellowship from the University of Padua supported by ONLUS Ricerca per Credere nella Vita (RCV), Padua, Italy.
: All patients gave consent to the publication of anonymous data.
: The datasets generated and analysed during the current study are not publicly available due to the data protection and lack of consent from the patients. Access to data is strictly limited to the researchers who have obtained permission for data processing.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).